gallivac reo liofilizāts un šķīdinātājs suspensijas injekcijām pagatavošanai
boehringer ingelheim animal health italia s.p.a, itālija - putnu reovirus celma (- u 1133) - liofilizāts un šķīdinātājs suspensijas injekcijām pagatavošanai - vistas
lubion 25 mg šķīdums injekcijām
ibsa farmaceutici italia s.r.l., italy - progesterons - Šķīdums injekcijām - 25 mg
meriofert 75 sv pulveris un šķīdinātājs injekciju šķīduma pagatavošanai
ibsa farmaceutici italia s.r.l., italy - menotrofīns - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 75 sv
meriofert 150 sv pulveris un šķīdinātājs injekciju šķīduma pagatavošanai
ibsa farmaceutici italia s.r.l., italy - menotrofīns - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 150 sv
meriofert 900 sv pulveris un šķīdinātājs injekciju šķīduma pagatavošanai
ibsa farmaceutici italia s.r.l., italy - menotrofīns - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 900 sv
lubion 25 mg šķīdums injekcijām pilnšļircē
ibsa farmaceutici italia s.r.l., italy - progesterons - Šķīdums injekcijām pilnšļircē - 25 mg
pifeltro
merck sharp & dohme b.v. - doravirine - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.
livtencity
takeda pharmaceuticals international ag ireland branch - maribavir - citomegalovīrusu infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). jāņem vērā oficiālās vadlīnijas par piemērotu izmantot pretvīrusu aģentu.
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cūkas - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
innovax-ilt
intervet international b.v. - ar šūnu saistītu dzīvu rekombinanto tītara herpes vīrusu (hvt / ilt-138 celms), kas ekspresē glikoproteīnu gd un infekciozā laringgotraķīta vīrusa gi - immunologicals par aves, dzīvu vīrusu vakcīnas - cālis - aktīvās imunizācijas vienu dienu veci cāļi, lai samazinātu mirstību, klīniskās pazīmes un bojājumu dēļ, inficēšanās ar putnu infekcijas laryngotracheitis (ilt) vīrusu un mareka slimība (md) vīruss.